Financial Analysis: Crescent Biopharma (NASDAQ:CBIO) and MannKind (NASDAQ:MNKD)

MannKind (NASDAQ:MNKD – Get Free Report) and Crescent Biopharma (NASDAQ:CBIO – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Profitability

This table compares MannKind and Crescent Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MannKind -18.10% N/A -10.01%
Crescent Biopharma N/A -88.20% -77.36%

Institutional and Insider Ownership

49.5% of MannKind shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for MannKind and Crescent Biopharma, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MannKind 1 2 7 0 2.60
Crescent Biopharma 1 0 5 1 2.86

MannKind currently has a consensus price target of $8.50, suggesting a potential upside of 108.85%. Crescent Biopharma has a consensus price target of $33.17, suggesting a potential upside of 167.47%. Given Crescent Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Crescent Biopharma is more favorable than MannKind.

Risk & Volatility

MannKind has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Valuation & Earnings

This table compares MannKind and Crescent Biopharma”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MannKind $348.97 million 3.75 $5.86 million ($0.23) -17.70
Crescent Biopharma $10.84 million 44.50 -$153.94 million ($6.35) -1.95

MannKind has higher revenue and earnings than Crescent Biopharma. MannKind is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Crescent Biopharma beats MannKind on 8 of the 14 factors compared between the two stocks.

About MannKind

(Get Free Report)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).

About Crescent Biopharma

(Get Free Report)

Crescent Biopharma is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on antibody-based treatments, including therapies designed to target tumor cells and support the body’s immune response. The company’s work is directed toward advancing oncology drug candidates through clinical development. Its pipeline and programs may change as research progresses, and its products are investigational rather than established treatments. Crescent Biopharma is focused on developing its therapies for cancer patients; detailed information about its geographic operations and leadership is not included here.

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.